Insulin human inhalation powder was approved by the FDA for use in June of 2014. This newly approved product offers an insulin administration technique and associated risk factors that current pharmacists are most likely unfamiliar with. This continuing education activity will provide pharmacists with introductory information about this new drug product.
The disclosure policies of the SIUE School of Pharmacy Office of Continuing Professional Education requires all persons in a position to control content to disclose any relevant financial relationships with commercial interests. If a conflict is identified, the Office of Professional Continuing Education will initiate a process for resolving the conflict. The existence of relationships does not necessarily imply bias or lessen the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The persons required to disclose conflicts include all course faculty, the SIUE CPE administrator, all activity planners and all reviewers. The relevant commercial financial relationships or affiliations must have occured over the past 12 months.
The participant must provide the correct NABP ePID number/DOB combination in their electronic profile. All CPE evaluations must be completed within 60 days of activity. It is the participant's responsibility to check that their credit records are correct within the 60 day period after completion of the activity. Log in to CPE Monitor at www.mycpemonitor.net to view a list of all ACPE-accredited activities you have taken. Any discrepancies must be resolved with the CPE Provider directly and in a timely manner.
Requirements for CE Credit
|You must complete a pre-test, a post-test with a pass rate of 75% and an activity evaluation form to obtain credit. Credit will be submitted through CPE Monitor.
I wish to thank Andrea Wooley, PharmD, BCACP, for her expert advice regarding this topic and in the preparation of this paper, Terri Poirier, PharmD, for her revision efforts, and Walter Siganga, RPh, PhD, for his assistance with completion of this issue.
- Identify which patients may benefit from the use of inhaled prandial insulin
- Describe important counseling points related to administration and storage
- List appropriate monitoring parameters for potential lung-related issues
- State contraindications for the use of inhaled prandial insulin
- Define common side effects of and contraindications for inhaled prandial insulin
Emily Donahue, PharmD 2015 Candidate
Brief Bio : I graduated from Western State Colorado University in 2011 with a BA in chemistry. Currently, I am a fourth year pharmacy student at Southern Illinois University Edwardsville School of Pharmacy. I plan to pursue a career in pharmacy where patient interaction is emphasized.
Disclosure : Emily Donahue has completed and submitted the SIUE School of Pharmacy Continuing Pharmacy Education Form for Disclosure of Potential Conflicts of Interest and none were reported.
Release Date: Dec 10, 2014
Credit Expiration Date: Dec 10, 2017